Yosprala is a once-daily tablet containing immediate-release omeprazole and delayed-release aspirin (ASA) indicated for patients who require ASA for secondary prevention of cardiovascular and cerebrovascular events and are at risk for developing ASA-associated gastric ulcers.1


Prescription-strength omeprazole with 2 aspirin strengths1

• Administered at least 1 hour before a meal1,*


81-mg delayed-release aspirin/
40-mg immediate-release omeprazole


325-mg delayed-release aspirin/
40-mg immediate-release omeprazole

*The tablets are to be swallowed whole with liquid. Do not split, chew, crush, or dissolve the tablet.1

For illustration purposes only. Not a visual representation of the tablets.


Remember these points when treating with Yosprala

Use the lowest effective dose of Yosprala based on the individual patient's treatment goals and to avoid potential dose-dependent adverse reactions, including bleeding.1

If a dose of Yosprala is missed, advise patients to take it as soon as it is remembered. If it is almost time for the next dose, skip the missed dose. Take the next dose at the regular time. Patients should not take 2 doses at the same time unless advised by their doctor.1

Do not stop taking Yosprala suddenly as this could increase the risk of heart attack or stroke.1

References: 1. Yosprala Prescribing Information. Charleston, WV: Innovida Pharmaceutique Corporation; 2018.

Yosprala® is a registered trademark of Genus Lifesciences, Inc. and is used under license. All other product/brand names are trademarks of their respective owners.
Manufactured for: Innovida Pharmaceutique Corporation © 2019 Innovida Pharmaceutique Corporation, Inc. All rights reserved. INY-01-001, Rev 05/2020